Vimarsana
Biggest News Aggregation in the World

Page 21 - Interim Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interim Analysis Today - Breaking & Trending Today

Interim Analyses During Group Sequential Clinical Trials - Vimarsana News

Interim Analyses During Group Sequential Clinical Trials

This JAMA Guide to Statistics and Methods describes why interim analyses are performed during group sequential trials, provides examples of the limitations of i

TNXP: Interim Analysis for Phase 3 RALLY Trial in 3Q21; Topline Results in 1Q22… - Vimarsana News

TNXP: Interim Analysis for Phase 3 RALLY Trial in 3Q21; Topline Results in 1Q22…

By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Tonix Pharmaceutical Holdings Corp. (NASDAQ:TNXP) has undergone a transformation over the past year as it has built up a robust pipeline of clinical stage assets focused on the treatment of central nervous system (CNS) and immunological diseases. In addition, the company’s balance sheet has never been stronger. As of March 31, 2021, Tonix had approximately $164.2...

Source: msn.com
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs - Vimarsana News

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral...

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine - Vimarsana News

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

Source: yahoo.com
Treace Announces Interim Results from ALIGN3D™ Clinical Study at ACFAS 2021 - Vimarsana News

Treace Announces Interim Results from ALIGN3D™ Clinical Study at ACFAS 2021

Message : Required fields PONTE VEDRA, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced positive interim results from the ALIGN3D™ clinical study in a podium presentation at the ongoing American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. Dr. George T. Liu, Associate Professor of Orthopae...